Table 2.
Clinical trials on PARP inhibitors in brain tumours. Summary table highlights the current PARP inhibitors in clinical trials for brain tumours.
| PARP Inhibitor | Clinical Trials | Indication | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Olaparib | Phase I | In combination with Temozolomide for the treatment of patients with relapsed glioblastoma | NCT01390571 |
| Phase II | Treatment of patients with advanced glioma, cholangiocarcinoma, or solid tumours with IDH1 or IDH2 mutations | NCT03212274 | |
| NMS-03305293 | Phase I | In combination with Temozolomide for the treatment of patients with diffuse gliomas | NCT04910022 |
| Phase II | In combination with Temozolomide for the treatment of patients with IDH wild type recurrent glioblastoma | ||
| Fluzoparil | Phase II | In combination with Temozolomide for the treatment of patients with recurrent glioblastoma | NCT04552977 |
| BGB-290 | Phase I/II | In combination with Temozolomide for the treatment of patients with recurrent gliomas with IDH1/2 mutations | NCT03914742 |
| Veliparib | Phase I | In combination with temozolomide work for the treatment of children with recurrent/refractory CNS tumours | NCT00994071 |
| Phase I | In combination with whole brain radiation therapy for the treatment of cancer patients with brain metastases | NCT00649207 | |
| Phase II | In combination with radiation therapy, and temozolomide for the treatment of patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations | NCT03581292 | |
| Phase II | In combination with radiation therapy, and temozolomide for the treatment of patients with newly diagnosed diffuse pontine gliomas | NCT01514201 | |
| Phase II | Cisplatin with or without Veliparib for the treatment of patients with recurrent or metastatic triple-negative and/or BRCA mutation-associated breast cancer with or without brain metastases | NCT02595905 | |
| Talazoparib | Phase II | In combination with Carboplatin for the treatment of patients with recurrent high-grade glioma | NCT04740190 |
| Niraparib | Early Phase I | Treatment of patients with newly diagnosed glioblastoma and recurrent glioma | NCT05076513 |
| Phase II | Treatment of patients with recurrent glioblastoma | NCT04221503 |